Plus Therapeutics Inc (PSTVZ) News

$PSTVZ: Looking fabulous for a sweet run



We just saw something like this recently............. cant remember ticker now



GO $PSTVZ

Pstvz premarket volume..uptick on bid

$PSTVZ: Thanks for the Private Message

Good to see you at MARK.


I've loaded even more now.


Sorry... can't do PMs anymore. Don't have subscription.


Also, very sorry for your loss.


May her light shine on you.


GO $MARK

PSTVZ warrants expire 5-21-20

Green Start!
Let's get .015 eod baby!

$PSTVZ: Whoever sold those 33s..........


THANK YOUUUUUuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuu




GO $PSTVZ

Holding on to my shares

I saw what AYTUZ did
Patients will pay off..
Go PSTVZ

Check out PHIOW also
Less than 500k float

Morning!
Looking forward to another strong day here. Also got my eye on MDGC about to do merger to start making ventilators currently at .0008. I'm new to this whole warrant gig, definitely watching PSTV's movement!

$PSTVZ: That was a pretty sweet close...........


Up to near $0.018 again from where it started.

Now we continue to monitor commons as those dictate further
upside here.


Lots of others on the market but this one has the look... like AYTUZ


GO $PSTVZ

I added today too. Thanks brother!

$PSTVZ: Awesome..... retested daily highs


Better to be here now rather than $AMRN.

It just too a massive beat down now in After Hours.

Stay safe out there.


GO $PSTVZ

Just a lil more volume and this thing will pop!

$PSTVZ: Nice dip here... in for another batch


of Cheaps.


Better here than getting them at $0.57



Thats the exit point.



GO $PSTVZ

Go PSTVZ

$PSTV: Commons were $22 just last September


By getting into NanoTX........... this a big boost for Plus Therapeutics.


Putting up $134Million for it too.


Great pickup for a return to glory for this oncology play.



GO $PSTVZ

I slapped more PSTVZ

GoPSTVZ

$PSTVZ: The $0.026 level about to go soon


Market is really starting pickup volume on warrants now that the
commons are on fire.


Should be a nice upside move to $0.57



GO $PSTVZ

I wish I bought more of AYTUZ only 100k

Nslpq and NUSPQ gave me a 1000% when you first alerted it...

I’m in for the ride

$PSTVZ: Here come buyers now............ another $0.011


This is playing out just like AYTUZ.

Volume is really adding up on this news today.


Market approves


You can match them............. line for line.



GO $PSTVZ

I’m bidding for more
Thanks once again

Please stay out of jail, we need you here

$PSTVZ: Your welcome.... glad you got that


This one here is gonna be really big for Plus.




GO $PSTVZ

Welcome back!!!
Got 100k with you
#goPSTVZ


Thanks for your alert on AYTUZ
Best trade ever

I was wondering wtf happened lol. Welcome back to the party. Picked up 100k this morning at 006 ??

$PSTVZ: Thanks much.................. in for another 50k


They like to keep me in Jail



Turns them on.



GO $PSTVZ

Glad to see ya back bro from your hiatus!

GLTY!

$PSTVZ: Nothing all the way up to $0.18


If you look closely.


Thin on the ask............. it can float.



GO $PSTVZ

$PSTVZ: Where will you be when we're at........


$0.58 ?????????



Just curious :)



GO $PSTVZ

$PSTVZ: Paying $137Million...............


You can only guess how much money $PSTV has if they are
ready to do that for Nano TX



GO $PSTVZ

$PSTVZ: Here they come....... in droves


Don't wanna miss how hard and fast it can really go.


$0.018s going........... big time.



GO $PSTVZ

$PSTVZ: Just hit $0.018.......... going like AYTUZ


People just don't see it .......... but its perfectly positioned.



GO $PSTVZ

Doesnt take much to move her

great buy here.. now

$PSTVZ: PSTVZ WTS PLUS THERAPEUTICS INC SERIES S WARRANT


Thanks for the opinion.



These are directly connected to Plus Therapeutics.


THe news is directly applicable.



Over 600k volume so far......... and more coming


GO $PSTVZ

The news is related to ticker PSTV.... Not PSTVZ... here is the news link

https://finance.yahoo.com/news/plus-therapeutics-licenses-novel-oncology-111510867.html

$PSTVZ: Now hitting $0.0079........... going to $0.25


Observe............ and learn :)


Piece of CAKE !!!!!!


We're here just in time.



GO $PSTVZ

Moving

$PSTVZ: AYTUZ went to $0.18............ and here we are


PSTV is killing it............ warrants about to be huge.



Only $0.005 right now




GO $PSTVZ

$PSTVZ: Massive news.............




Get ready for a biggggggggggggggggg move here.


Now super cheap at $0.01

You saw $AYTUZ move to $0.18 on $AYTU.


Time for $PSTVZ to roll as well............ pretty hard



GO $PSTVZ


***************************************************




Plus Therapeutics Licenses Cancer Drug Product Candidates From NanoTx
7:25 AM ET 3/30/20 | Dow Jones
Related Quotes


3:58 PM ET 3/27/20
Symbol Last % Chg
PSTV
1.44 0.00%
Real time quote.



By Chris Wack

Plus Therapeutics Inc. said Monday it agreed to license multiple rare cancer drug product candidates from private Texas-based radiotherapeutic company NanoTx Therapeutics Inc.

The pharmaceutical company said transaction terms include an upfront payment of $400,000 in cash to NanoTx and $300,000 in Plus voting stock.

Plus may pay up to $136.5 million in development and sales milestone payments and a tiered single-digit royalty on U.S. and European sales. The transaction is expected to close in the second quarter of 2020.

Plus said the licensed drug portfolio is anchored around nanoliposome-encapsulated radionuclides for several cancer targets. Plus is licensing multiple BMEDA-chelated rhenium nanoliposome product candidates as part of this transaction.

Plus Therapeutics shares were up 30% to $1.87 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

> Dow Jones Newswires

March 30, 2020 07:25 ET (11:25 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

$PSTVZ: Very positive update today.... 2020 Expansion


Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020
7:15 AM ET 1/6/20 | GlobeNewswire
Related Quotes


4:00 PM ET 1/3/20
Symbol Last % Chg
PSTV
2.50 0.00%
Real time quote.



Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020

AUSTIN, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today issued the following Letter to Shareholders from Dr. Marc Hedrick, President and Chief Executive Officer.

January 6, 2020

To Our Loyal Stockholders:

All of us at Plus Therapeutics wish you and yours a healthy and productive new year. We greatly appreciate your dedication to this company over the years and we are confident that 2020 will demonstrate that your loyalty was well-placed.

As we emerge from a successful transitional year for the company, we enter 2020 with a clear mission, expansive vision, and straightforward development model. Plus Therapeutics is on a mission to discover, develop and deliver complex and innovative treatments for patients battling cancer and rare diseases. This mission is designed to fulfill our vision of introducing medicines that drastically enhance clinical and economic outcomes for patients and providers -- and dramatically improve human health worldwide. Our development model starts with a proven drug and applies new delivery and formulation innovations to unlock and achieve new clinical applications for or improved safety and efficacy of the proven drug.

We are pleased to say that we have positioned ourselves to fulfill that vision beginning this year. We have a sharp focus on drugs that can be developed cost-effectively and efficiently. We are quickening our business pace, in part, by utilizing U.S. FDA regulatory pathways such as the 505(b)(2) New Drug Application, designed to streamline development of pharmaceutical products that incorporate already-approved pharmacological agents. And we are leveraging our core expertise in drug reformulation through nanoparticle encapsulation and delivery of proven workhorse oncology drugs.

At the same time, we have re-architected this company for growth. As I have said recently:

"Plus Therapeutics emerges from 2019 with the financial strength, development focus and cost structure to achieve long-term viability and growth. This company is now poised to convert its development vanguard position into market leadership. We are confident that our expanding pipeline can produce extraordinary drugs that provide tremendous benefits to patients and shareholders alike."

I am extremely proud of our team, which worked tirelessly in 2019 to bring us to this point. In quick succession, during the second half of 2019 this company:

-- Reinvented as a clinical-stage pharmaceutical company focused on oncology

and rare disease;

-- Achieved long-term viability in a rapid burst of financial milestones,

adding approximately $26 million to the balance sheet through a series of

transactions including the sale of non-core assets, a $4.6 million

reimbursement from the U.S. Department of Health and Human Services for

our work on our BARDA contract, and a $15 million public offering;

-- Moved our corporate headquarters from California to the

lower-cost/lower-tax/incentive-friendly state of Texas, whose Cancer

Prevention & Research Institute is the largest public funder of cancer

research in the U.S. after the federal government; and

-- Right-sized into a lean organization built-for-scale at sustainable

margin.

Our nanotechnology platform is designed to generate enhanced delivery of drugs using novel liposomal encapsulation technology. Our lead product candidate, DocePLUS, is a protein-stabilized PEGylated liposomal formulation of docetaxel, for which the process of preparation is patented. The active pharmaceutical ingredient, docetaxel, was approved by the U.S. FDA in 1999 and commonly used for treating cancers of the breast, head, neck, stomach, prostate, and lung. Further, we are looking to divest another pipeline product candidate, DoxoPLUS, PEGylated liposomal doxorubicin, a generic version of CAELYX, used for the treatment of ovarian and breast cancers.

In 2019, we received positive pre-IND feedback from U.S. FDA, and we believe strongly that there is a path forward for our DocePLUS product candidate. We expect to finalize our Phase 2 clinical protocol with U.S. FDA in the 1(st) half of 2020 and treat the first patients in the 2(nd) half of 2020.

The portfolio is designed to put the "plus" in PLUS. Each of our drug candidates must meet three basic criteria:

1) Addresses an unmet or substantially underserved medical need;

2) Deploys new technologies to more safely and effectively deliver known active pharmaceutical ingredients that have extensive pre-existing safety and efficacy information; and

3) Serves an addressable global market opportunity of at least $250 million annually.

Please stay tuned in 2020 for potential additions to our portfolio.

Once again, I offer our heartfelt thanks -- to our team, to our Board, to our partners and to our shareholders. We are grateful for your continued support. And we look forward to an excellent year in 2020.

Sincerely,

Dr. Marc Hedrick

President and Chief Executive Officer

About Plus Therapeutics, Inc.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing scale up of complex and innovative treatments for patients battling cancer and other life-threatening diseases.

Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers.

Our lead product candidate, DocePLUS, is a protein-stabilized PEGylated liposomal formulation of docetaxel, for which the process of preparation is patented. The active pharmaceutical ingredient, docetaxel, was approved by the U.S. FDA in 1999 and commonly used for treating cancers of the breast, head, neck, stomach, prostate, and lung. More information may be obtained at plustherapeutics.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company's belief that that its expanding pipeline can produce extraordinary drugs that provide tremendous benefits to patients and shareholders alike; the Company's plans to divest another pipeline product candidate, DoxoPLUS; the Company's expectations regarding finalizing its Phase 2 clinical protocol with U.S. FDA in the 1st half of 2020 and treat the first patients in the 2nd half of 2020; the Company's potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; and the Company's potential to substantially improve the lives of patients battling cancer and rare diseases. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the U.S. FDA does not accept the Company's submission of a Phase 2 clinical trial protocol; the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA's accelerated regulatory pathways; the ability of the Company to raise additional capital to meet the Company's business operational needs and to achieve its business objectives and strategy; the Company's ability to project future capital needs and cash utilization; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; and the risks described under the heading "Risk Factors" in the Company's Securities and Exchange Commission filings, including in the Company's annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Plus Therapeutics, Inc.

Russ Havranek

VP -- Marketing, Portfolio Management, Investor Relations

Phone: +1.619.333.4150

Email: ir@plustherapeutics.com

Website: plustherapeutics.com

> Dow Jones Newswires

January 06, 2020 07:15 ET (12:15 GMT)

$PSTVZ: The time is coming....... I can feel it




Got 300k of these



Watch for the $PSTV move to lift these bad boys up.


$0.01 right now... SUPER STEAL



GO $PSTVZ

That was a crazy big buy, someone might lose the butt here, he’s already down over 50% ouch

Huge bid

Oh ok. Looks like they are going to run premarket

PSTVZ is the warrants for PSTV. If PSTV pops back over 20, then we pop with it.

I bought in at .0413 looking for a nice tune soon. I see the other company PSTV is the same they are running also. 19$ per share

Who bought .20? Lol

I bought 10k at .04 that’s all.. I have no idea what’s going on here

yankees18...OMG...WHAT S HUGE FIND!!!...HITTING .20 ALREADY PRE-MARKET..COULD GO TO $1.00+ FAST !!!!...WOW.

PSTVZ $$$ GETTING READY FOR A MONSTER MOVE !!! COULD SEE 0.50-1.00 FAST, ESPECIALLY WITH PSTV AT $18.00+ AND GOING HIGHER !!

After hours, up nearly 500%

AH hit